3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
3
Status
Recruiting
3
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Conditions
Breast Neoplasms
7
Carcinoma, Non-Small-Cell Lung
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Lung Neoplasms
3
Esophageal Neoplasms
3
Neoplasms
2
Neoplasm Metastasis
2
Brain Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Solid Tumor, Adult
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Non-Small Cell Lung Cancer Metastatic
1
Meningeal Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer
1
Endometrial Neoplasms
1
Interventions
pembrolizumab
119
Cisplatin
33
lenvatinib
29
Carboplatin
28
Paclitaxel
27
Docetaxel
14
Pemetrexed
13
Fluorouracil
12
Capecitabine
11
Saline Solution
10
Oxaliplatin
10
Gemcitabine
10
Albumin-Bound Paclitaxel
7
olaparib
6
Leucovorin
6
Bevacizumab
6
epacadostat
5
belzutifan
5
Etoposide
5
Cetuximab
5
130-nm albumin-bound paclitaxel
5
trifluridine tipiracil drug combination
3
regorafenib
3
patritumab deruxtecan
3
enzalutamide
3
enfortumab vedotin
3
durvalumab
3
Surgical Procedures, Operative
3
Radiotherapy
3
Levoleucovorin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
patritumab deruxtecan
×
1 year
×
Clear all
NCT06469944
2026-05-26
MK-3475-06C
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
160 enrolled
NCT04165070
2026-05-18
MK-3475-01A
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
450 enrolled
NCT06445972
2026-05-12
MK-3475-06D
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
210 enrolled